Click here to get full coverage on HCC’s ‘Lavender Ball’ - Smoky Mountain News

HCC’s ‘Lavender Ball’  Smoky Mountain News

HCC’s ‘Lavender Ball’ - Smoky Mountain News

Click here to get full coverage on Systemic Therapy and Downstaging in Unresectable, Nonmetastatic HCC - OncLive

Systemic Therapy and Downstaging in Unresectable, Nonmetastatic HCC  OncLive

Systemic Therapy and Downstaging in Unresectable, Nonmetastatic HCC - OncLive

Click here to get full coverage on HCC Subgroups May Guide Personalized Treatment, Patient Selection - Docwire News

HCC Subgroups May Guide Personalized Treatment, Patient Selection  Docwire News

HCC Subgroups May Guide Personalized Treatment, Patient Selection - Docwire News

Click here to get full coverage on Could Contrast-Enhanced Ultrasound Offer Equivalency to MRI for Detecting Small HCC Nodules? - diagnosticimaging.com

Could Contrast-Enhanced Ultrasound Offer Equivalency to MRI for Detecting Small HCC Nodules?  diagnosticimaging.com

Could Contrast-Enhanced Ultrasound Offer Equivalency to MRI for Detecting Small HCC Nodules? - diagnosticimaging.com

Click here to get full coverage on Tokio Marine HCC Ratings Affirmed and Outlook Raised to Positive By S&P Global Ratings - GlobeNewswire

Tokio Marine HCC Ratings Affirmed and Outlook Raised to Positive By S&P Global Ratings  GlobeNewswire

Tokio Marine HCC Ratings Affirmed and Outlook Raised to Positive By S&P Global Ratings - GlobeNewswire

Click here to get full coverage on CEUS with perfluorobutane diagnoses small-cell HCC - AuntMinnie

CEUS with perfluorobutane diagnoses small-cell HCC  AuntMinnie

CEUS with perfluorobutane diagnoses small-cell HCC - AuntMinnie

Click here to get full coverage on Transcriptional factor ZMYM3 promotes hepatocellular carcinoma metastasis by upregulating CTTN and inducing invadopodia formation | Cell Death & Disease - Nature

Transcriptional factor ZMYM3 promotes hepatocellular carcinoma metastasis by upregulating CTTN and inducing invadopodia formation | Cell Death & Disease  Nature

Transcriptional factor ZMYM3 promotes hepatocellular carcinoma metastasis by upregulating CTTN and inducing invadopodia formation | Cell Death & Disease - Nature

Click here to get full coverage on Holyoke Community College gets $245K grant to expand child care center - WWLP

Holyoke Community College gets $245K grant to expand child care center  WWLP

Holyoke Community College gets $245K grant to expand child care center - WWLP

Click here to get full coverage on Cadiz Rotary Club Hears Update On HCC Early College Program - WKDZ

Cadiz Rotary Club Hears Update On HCC Early College Program  WKDZ

Cadiz Rotary Club Hears Update On HCC Early College Program - WKDZ

Click here to get full coverage on Upper Limb Paralysis as Presentation of Hepatocellular Carcinoma Bone Metastases - Cureus

Upper Limb Paralysis as Presentation of Hepatocellular Carcinoma Bone Metastases  Cureus

Upper Limb Paralysis as Presentation of Hepatocellular Carcinoma Bone Metastases - Cureus

Click here to get full coverage on ISU and HCC strengthen partnership with new articulation agreements - Yahoo

ISU and HCC strengthen partnership with new articulation agreements  Yahoo

ISU and HCC strengthen partnership with new articulation agreements - Yahoo

Click here to get full coverage on Warrior Met Coal $HCC Stake Lifted by Kennondale Capital Management LLC - MarketBeat

Warrior Met Coal $HCC Stake Lifted by Kennondale Capital Management LLC  MarketBeat

Warrior Met Coal $HCC Stake Lifted by Kennondale Capital Management LLC - MarketBeat

Click here to get full coverage on Blood test aims to spot deadly liver cancer earlier in cirrhosis - Stock Titan

Blood test aims to spot deadly liver cancer earlier in cirrhosis  Stock Titan

Blood test aims to spot deadly liver cancer earlier in cirrhosis - Stock Titan

Click here to get full coverage on Explore new ideas at HCC’s Flower and Garden Show this March - The Herald-Mail

Explore new ideas at HCC’s Flower and Garden Show this March  The Herald-Mail

Explore new ideas at HCC’s Flower and Garden Show this March - The Herald-Mail

Click here to get full coverage on TRIPLET-HCC at ESMO 2025: Adding Ipilimumab to Atezolizumab–Bevacizumab Fails to Improve Outcomes in Unresectable HCC - Oncodaily

TRIPLET-HCC at ESMO 2025: Adding Ipilimumab to Atezolizumab–Bevacizumab Fails to Improve Outcomes in Unresectable HCC  Oncodaily

TRIPLET-HCC at ESMO 2025: Adding Ipilimumab to Atezolizumab–Bevacizumab Fails to Improve Outcomes in Unresectable HCC - Oncodaily

Click here to get full coverage on FDA Grants Fast Track Designation to Irpagratinib in FGF19-Overexpressed HCC - CancerNetwork

FDA Grants Fast Track Designation to Irpagratinib in FGF19-Overexpressed HCC  CancerNetwork

FDA Grants Fast Track Designation to Irpagratinib in FGF19-Overexpressed HCC - CancerNetwork

Click here to get full coverage on Rays stadium proposal gains momentum after unveiling new rendering - Sports Talk Florida

Rays stadium proposal gains momentum after unveiling new rendering  Sports Talk Florida

Rays stadium proposal gains momentum after unveiling new rendering - Sports Talk Florida

Click here to get full coverage on Combining tissue-derived microRNAs with clinical risk models for prediction of HCC recurrence after liver transplantation: A proof-of-concept study | Scientific Reports - Nature

Combining tissue-derived microRNAs with clinical risk models for prediction of HCC recurrence after liver transplantation: A proof-of-concept study | Scientific Reports  Nature

Combining tissue-derived microRNAs with clinical risk models for prediction of HCC recurrence after liver transplantation: A proof-of-concept study | Scientific Reports - Nature

Click here to get full coverage on Atezolizumab Plus Bevacizumab Shows Early TTFS Edge Over TACE in HCC - OncLive

Atezolizumab Plus Bevacizumab Shows Early TTFS Edge Over TACE in HCC  OncLive

Atezolizumab Plus Bevacizumab Shows Early TTFS Edge Over TACE in HCC - OncLive

Click here to get full coverage on Will the Rays include HCC? School urging team to incorporate college in stadium development plans - FOX 13 Tampa Bay

Will the Rays include HCC? School urging team to incorporate college in stadium development plans  FOX 13 Tampa Bay

Will the Rays include HCC? School urging team to incorporate college in stadium development plans - FOX 13 Tampa Bay

Click here to get full coverage on Tiragolumab/Atezolizumab/Bevacizumab Fails to Significantly Improve PFS in Advanced/Metastatic HCC - OncLive

Tiragolumab/Atezolizumab/Bevacizumab Fails to Significantly Improve PFS in Advanced/Metastatic HCC  OncLive

Tiragolumab/Atezolizumab/Bevacizumab Fails to Significantly Improve PFS in Advanced/Metastatic HCC - OncLive

Click here to get full coverage on The origin of hepatocellular carcinoma depends on metabolic zonation - Science | AAAS

The origin of hepatocellular carcinoma depends on metabolic zonation  Science | AAAS

The origin of hepatocellular carcinoma depends on metabolic zonation - Science | AAAS

Click here to get full coverage on Notable Tuesday Option Activity: CEG, HCC, SMTC - Nasdaq

Notable Tuesday Option Activity: CEG, HCC, SMTC  Nasdaq

Notable Tuesday Option Activity: CEG, HCC, SMTC - Nasdaq

Click here to get full coverage on CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy - PR Newswire

CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy  PR Newswire

CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy - PR Newswire

Click here to get full coverage on Atezolizumab Plus Bevacizumab Shows Potential Advantage Over TACE in Intermediate-Stage HCC - OncLive

Atezolizumab Plus Bevacizumab Shows Potential Advantage Over TACE in Intermediate-Stage HCC  OncLive

Atezolizumab Plus Bevacizumab Shows Potential Advantage Over TACE in Intermediate-Stage HCC - OncLive

Click here to get full coverage on Patient Selection and Contraindications for Immunotherapy in Unresectable HCC - OncLive

Patient Selection and Contraindications for Immunotherapy in Unresectable HCC  OncLive

Patient Selection and Contraindications for Immunotherapy in Unresectable HCC - OncLive

Click here to get full coverage on On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC - OncLive

On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC  OncLive

On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC - OncLive

Click here to get full coverage on Selection of Immunotherapy Doublet Regimens for Patients With Unresectable HCC - OncLive

Selection of Immunotherapy Doublet Regimens for Patients With Unresectable HCC  OncLive

Selection of Immunotherapy Doublet Regimens for Patients With Unresectable HCC - OncLive

Click here to get full coverage on VAST Academy at HCC offers special needs students boost to pursue careers, education - FOX 26 Houston

VAST Academy at HCC offers special needs students boost to pursue careers, education  FOX 26 Houston

VAST Academy at HCC offers special needs students boost to pursue careers, education - FOX 26 Houston

Click here to get full coverage on GPC3 Offers Highly Specific Target in HCC - OncLive

GPC3 Offers Highly Specific Target in HCC  OncLive

GPC3 Offers Highly Specific Target in HCC - OncLive

Click here to get full coverage on Is there still a role for anti-TIGIT therapy in hepatocellular carcinoma? - ESMO Daily Reporter

Is there still a role for anti-TIGIT therapy in hepatocellular carcinoma?  ESMO Daily Reporter

Is there still a role for anti-TIGIT therapy in hepatocellular carcinoma? - ESMO Daily Reporter

Click here to get full coverage on Decoding the molecular and genomic landscape of hepatocellular carcinoma: biomarker discovery, classification frameworks, and therapeutic targeting - Nature

Decoding the molecular and genomic landscape of hepatocellular carcinoma: biomarker discovery, classification frameworks, and therapeutic targeting  Nature

Decoding the molecular and genomic landscape of hepatocellular carcinoma: biomarker discovery, classification frameworks, and therapeutic targeting - Nature

Click here to get full coverage on Potential Rays owner considering HCC as stadium site - FOX 13 Tampa Bay

Potential Rays owner considering HCC as stadium site  FOX 13 Tampa Bay

Potential Rays owner considering HCC as stadium site - FOX 13 Tampa Bay

Click here to get full coverage on ICI Use Does Not Significantly Affect EOL Outcomes in HCC - OncLive

ICI Use Does Not Significantly Affect EOL Outcomes in HCC  OncLive

ICI Use Does Not Significantly Affect EOL Outcomes in HCC - OncLive

Click here to get full coverage on Mayo Clinic uses investigational targeted radiopharmaceutical theranostic for hepatocellular carcinoma in first-in-human clinical trial - Mayo Clinic News Network

Mayo Clinic uses investigational targeted radiopharmaceutical theranostic for hepatocellular carcinoma in first-in-human clinical trial  Mayo Clinic News Network

Mayo Clinic uses investigational targeted radiopharmaceutical theranostic for hepatocellular carcinoma in first-in-human clinical trial - Mayo Clinic News Network

Click here to get full coverage on SIERRA Study in ESMO GI 2025: Efficacy of STRIDE in HCC - Oncodaily

SIERRA Study in ESMO GI 2025: Efficacy of STRIDE in HCC  Oncodaily

SIERRA Study in ESMO GI 2025: Efficacy of STRIDE in HCC - Oncodaily

Click here to get full coverage on Frontline Nivolumab/Ipilimumab Delivers Long-Term Efficacy in Unresectable HCC - OncLive

Frontline Nivolumab/Ipilimumab Delivers Long-Term Efficacy in Unresectable HCC  OncLive

Frontline Nivolumab/Ipilimumab Delivers Long-Term Efficacy in Unresectable HCC - OncLive

Click here to get full coverage on HCC retires jersey of former soccer star killed in Springfield shooting - WWLP

HCC retires jersey of former soccer star killed in Springfield shooting  WWLP

HCC retires jersey of former soccer star killed in Springfield shooting - WWLP

Click here to get full coverage on Assessing Warrior Met Coal (HCC) Valuation After Strong Quarter And Blue Creek Production Progress - simplywall.st

Assessing Warrior Met Coal (HCC) Valuation After Strong Quarter And Blue Creek Production Progress  simplywall.st

Assessing Warrior Met Coal (HCC) Valuation After Strong Quarter And Blue Creek Production Progress - simplywall.st

Click here to get full coverage on Comparable Treatment Outcomes Are Observed for Child-Pugh B in HCC - Targeted Oncology

Comparable Treatment Outcomes Are Observed for Child-Pugh B in HCC  Targeted Oncology

Comparable Treatment Outcomes Are Observed for Child-Pugh B in HCC - Targeted Oncology

Click here to get full coverage on Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma - The Manila Times

Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma  The Manila Times

Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma - The Manila Times

Click here to get full coverage on Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria - Nature

Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria  Nature

Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria - Nature

Click here to get full coverage on Celebrating the Life of HCC 'Founding Father' Edward L. Cochran, Jr. - Substack

Celebrating the Life of HCC 'Founding Father' Edward L. Cochran, Jr.  Substack

Celebrating the Life of HCC 'Founding Father' Edward L. Cochran, Jr. - Substack

Click here to get full coverage on Irpagratinib Plus Atezolizumab Is Safe and Effective in FGF19+ Advanced HCC - OncLive

Irpagratinib Plus Atezolizumab Is Safe and Effective in FGF19+ Advanced HCC  OncLive

Irpagratinib Plus Atezolizumab Is Safe and Effective in FGF19+ Advanced HCC - OncLive

Click here to get full coverage on Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial - The Lancet

Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial  The Lancet

Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial - The Lancet

Click here to get full coverage on ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment - Oncodaily

ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment  Oncodaily

ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment - Oncodaily

Click here to get full coverage on Backed by $767,500 National Science Foundation Grant, HCC Plans New Cybersecurity Degree Targeting High-Demand Jobs - Substack

Backed by $767,500 National Science Foundation Grant, HCC Plans New Cybersecurity Degree Targeting High-Demand Jobs  Substack

Backed by $767,500 National Science Foundation Grant, HCC Plans New Cybersecurity Degree Targeting High-Demand Jobs - Substack

Click here to get full coverage on STRIDE Regimen Shows Sustained 5-Year OS Benefit in Unresectable HCC - Targeted Oncology

STRIDE Regimen Shows Sustained 5-Year OS Benefit in Unresectable HCC  Targeted Oncology

STRIDE Regimen Shows Sustained 5-Year OS Benefit in Unresectable HCC - Targeted Oncology

Click here to get full coverage on CDC25C downregulation suppresses HCC growth via mitochondrial stress-induced autophagy and apoptosis - Nature

CDC25C downregulation suppresses HCC growth via mitochondrial stress-induced autophagy and apoptosis  Nature

CDC25C downregulation suppresses HCC growth via mitochondrial stress-induced autophagy and apoptosis - Nature

Click here to get full coverage on GPC3-targeted immunoPET allows for early detection of HCC: a pilot clinical study - Journal of Nuclear Medicine

GPC3-targeted immunoPET allows for early detection of HCC: a pilot clinical study  Journal of Nuclear Medicine

GPC3-targeted immunoPET allows for early detection of HCC: a pilot clinical study - Journal of Nuclear Medicine

Click here to get full coverage on New program training HCC students to be mechanics aims to tackle City of Tampa workforce shortage - FOX 13 Tampa Bay

New program training HCC students to be mechanics aims to tackle City of Tampa workforce shortage  FOX 13 Tampa Bay

New program training HCC students to be mechanics aims to tackle City of Tampa workforce shortage - FOX 13 Tampa Bay

Click here to get full coverage on Allwyn International terminates bid to acquire Novibet - Gaming Intelligence

Allwyn International terminates bid to acquire Novibet  Gaming Intelligence

Allwyn International terminates bid to acquire Novibet - Gaming Intelligence

Click here to get full coverage on FDA Approves Y-90 Resin Microspheres for Unresectable HCC - OncLive

FDA Approves Y-90 Resin Microspheres for Unresectable HCC  OncLive

FDA Approves Y-90 Resin Microspheres for Unresectable HCC - OncLive

Click here to get full coverage on A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial - Nature

A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial  Nature

A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial - Nature

Click here to get full coverage on Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target - OncLive

Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target  OncLive

Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target - OncLive

Click here to get full coverage on Celebrating the Life of HCC Founding Professor Emeritus James Bell - Substack

Celebrating the Life of HCC Founding Professor Emeritus James Bell  Substack

Celebrating the Life of HCC Founding Professor Emeritus James Bell - Substack

Click here to get full coverage on HCC changing name to ‘Houston City College’ in rebrand projected to cost $2.8 million - Houston Public Media

HCC changing name to ‘Houston City College’ in rebrand projected to cost $2.8 million  Houston Public Media

HCC changing name to ‘Houston City College’ in rebrand projected to cost $2.8 million - Houston Public Media

Click here to get full coverage on Exploring Differences in Survival With Lenvatinib in Recent HCC Trials - Targeted Oncology

Exploring Differences in Survival With Lenvatinib in Recent HCC Trials  Targeted Oncology

Exploring Differences in Survival With Lenvatinib in Recent HCC Trials - Targeted Oncology

Click here to get full coverage on Combinations show promise in hepatocellular carcinoma populations with poor prognosis - ESMO Daily Reporter

Combinations show promise in hepatocellular carcinoma populations with poor prognosis  ESMO Daily Reporter

Combinations show promise in hepatocellular carcinoma populations with poor prognosis - ESMO Daily Reporter

Click here to get full coverage on Atezolizumab and bevacizumab after TACE prolongs PFS in HCC - ESMO Daily Reporter

Atezolizumab and bevacizumab after TACE prolongs PFS in HCC  ESMO Daily Reporter

Atezolizumab and bevacizumab after TACE prolongs PFS in HCC - ESMO Daily Reporter

Click here to get full coverage on Nivolumab/Ipilimumab Establishes Unprecedented Efficacy and Safety Standards in Advanced HCC - OncLive

Nivolumab/Ipilimumab Establishes Unprecedented Efficacy and Safety Standards in Advanced HCC  OncLive

Nivolumab/Ipilimumab Establishes Unprecedented Efficacy and Safety Standards in Advanced HCC - OncLive

Click here to get full coverage on The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment - The Lancet

The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment  The Lancet

The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment - The Lancet

Click here to get full coverage on HCC announces new North Carolina university transfer agreements - Smoky Mountain News

HCC announces new North Carolina university transfer agreements  Smoky Mountain News

HCC announces new North Carolina university transfer agreements - Smoky Mountain News

Click here to get full coverage on CircSMEK1 Suppresses HCC via the hnRNPK-IGF2-AKT Axis: A Diagnostic Biomarker and Therapeutic Target - Wiley

CircSMEK1 Suppresses HCC via the hnRNPK-IGF2-AKT Axis: A Diagnostic Biomarker and Therapeutic Target  Wiley

CircSMEK1 Suppresses HCC via the hnRNPK-IGF2-AKT Axis: A Diagnostic Biomarker and Therapeutic Target - Wiley

Click here to get full coverage on Integrative genomics characterizes HCC eRNAs for prognosis and targeted therapy | Scientific Reports - Nature

Integrative genomics characterizes HCC eRNAs for prognosis and targeted therapy | Scientific Reports  Nature

Integrative genomics characterizes HCC eRNAs for prognosis and targeted therapy | Scientific Reports - Nature

Click here to get full coverage on HCC Launches 12-Week Employee Strength and Wellness Program - Substack

HCC Launches 12-Week Employee Strength and Wellness Program  Substack

HCC Launches 12-Week Employee Strength and Wellness Program - Substack

Click here to get full coverage on Area briefs: HCC to celebrate expanded child watch center - Daily Hampshire Gazette

Area briefs: HCC to celebrate expanded child watch center  Daily Hampshire Gazette

HCC

Price Chart

Key Statistics

Technicals

About HCC

Latest News

HCC’s ‘Lavender Ball’ - Smoky Mountain News

Systemic Therapy and Downstaging in Unresectable, Nonmetastatic HCC - OncLive

HCC Subgroups May Guide Personalized Treatment, Patient Selection - Docwire News

Advanced Charts

Top Gainers

Top Losers